Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2009
At a glance
- Drugs Hyaluronidase (Primary) ; Bisphosphonates
- Indications Osteoporosis
- Focus Adverse reactions
- Sponsors Halozyme Therapeutics
- 16 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Jan 2009 New trial record.